BioSenic, a biotech company, reports progress in its autoimmune and inflammatory disease platforms. The company has received a patent for the use of metal ions to enhance the therapeutic effects of arsenic, paving the way for clinical and commercial developments in autoimmunity and oncology. BioSenic plans to use its intellectual property portfolio to support international clinical trials and seek market access approvals for its formulations. The company is focusing on the accelerated development of its autoimmune (ATO/OATO) platform.

BioSenic's Progress and Patent